Vascular Endothelial Growth Factor Receptor-2
-
Subject Areas on Research
-
A comparison of antiangiogenic therapies for the prevention of liver metastases.
-
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression.
-
Aging is not associated with bone marrow-resident progenitor cell depletion.
-
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.
-
Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells.
-
Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.
-
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
-
Cell-Demanded VEGF Release via Nanocapsules Elicits Different Receptor Activation Dynamics and Enhanced Angiogenesis.
-
Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity.
-
Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.
-
Common endothelial progenitor cell assays identify discrete endothelial progenitor cell populations.
-
Conditional HIF-1 induction produces multistage neovascularization with stage-specific sensitivity to VEGFR inhibitors and myeloid cell independence.
-
Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries.
-
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
-
Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.
-
Effect of pazopanib on tumor microenvironment and liposome delivery.
-
Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma.
-
Endoglin interacts with VEGFR2 to promote angiogenesis.
-
Hypoxic Gene Expression of Donor Bronchi Linked to Airway Complications after Lung Transplantation.
-
IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species--dependent endothelial migration and proliferation.
-
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
-
Late outgrowth endothelial progenitor cells in patients with age-related macular degeneration.
-
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.
-
NgBR is essential for endothelial cell glycosylation and vascular development.
-
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
-
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
-
Reduction of Stat3 activity attenuates HIV-induced kidney injury.
-
Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
-
Regulation of blood vessel versus lymphatic vessel growth in the cornea.
-
Relationship of smoking and fibrosis in patients with chronic hepatitis C.
-
Synergistic induction of mitogen-activated protein kinase phosphatase-1 by thrombin and epidermal growth factor requires vascular endothelial growth factor receptor-2.
-
Synergy between tumor immunotherapy and antiangiogenic therapy.
-
Targeted inhibition of VEGF receptor 2: an update on ramucirumab.
-
Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer.
-
Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis.
-
The Flk1-myr::mCherry mouse as a useful reporter to characterize multiple aspects of ocular blood vessel development and disease.
-
The effect of vascular endothelial growth factor (VEGF) presentation within fibrin matrices on endothelial cell branching.
-
The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.
-
The phosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) by engineered surfaces with electrostatically or covalently immobilized VEGF.
-
Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level.
-
Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers.
-
VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model.
-
VEGF internalization is not required for VEGFR-2 phosphorylation in bioengineered surfaces with covalently linked VEGF.
-
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
-
Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.
-
Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.
-
Vascular-targeted photothermal therapy of an orthotopic murine glioma model.